紫杉醇联合替吉奥一线治疗晚期胃癌25例生存分析

Survival Analysis Paclitaxel Combined Tegafur as First-Line Chemotherapy for Patients with Advanced Gastric Cancer in 25 Cases

目的观察紫杉醇联合替吉奥一线治疗晚期胃癌的疗效和毒性。方法纳入28例晚期胃癌患者,采用3周治疗方案,紫杉醇175 mg/m2,第1天静脉注射3 h;替吉奥依据体表面积(<1.25 m2,40 mg;1.25～1.5 m2,50 mg;>1.5 m2,60 mg)连服第1至14天,1天2次,早晚口服。结果共25例纳入分析,年龄35～75岁,平均(60.2±10.51)岁。其中部分缓解14例,无完全缓解病例,总有效率达56.00%。中位生存期15.5个月,1年生存率为76.00%,中位无进展生存时间为8个月。最常见的Ⅲ/Ⅳ度毒性为贫血(24.00%),粒细胞减少(16.00%)和白细胞减少(16.00%)。结论紫杉醇联合替吉奥3周方案治疗晚期胃癌毒性可以耐受,疗效良好。

Objective We used combination therapy of tcgafur and paclitaxel to treat advanced gastric cancer and assessed the efficacy and toxicity. Methods This study included 28 patients with advanced gastric cancer, which were treated with tri- weekly administration of tegafur（according to body surface area,〈 1.25 m^2,40 mg; 1.25 - 1.5 m^2,50 mg;〉 1.5 mZ,60 mg） orally,continuously for 2 weeks,and paclitaxel （175 mg/m^2） on day 1 of S- 1 administration. Results Twenty-five patients were included for analysis. The mean age of the patients was 60.2± 10.51 years （35-75 y）. Fourteen cases were obtained partial response,and no complete response was observed. The overall response rate was 56.00%. The median survival was 15.5 months, the survival for 1 year was 76.00%, the median survival with no progress was 8 month. The frequent grade 3/4 toxic effects included anemia （24.00%）,neutropenia （16.00%）,and leukopenia （16.00%）.